

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Meihao Medical Group Co., Ltd**  
**美皓醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1947)**

**(1) RE-DESIGNATION OF DIRECTOR;**  
**(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;**  
**AND**  
**(3) CHANGE OF MEMBERS OF AUDIT COMMITTEE AND**  
**NOMINATION COMMITTEE**

**(1) RE-DESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Meihao Medical Group Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effect from 29 November 2024, Dr. Zhou Jian (“**Dr. Zhou**”) has been re-designated from an independent non-executive Director to an executive Director and ceased to be a member of the audit committee of the Company (the “**Audit Committee**”) and of the nomination committee of the Company (the “**Nomination Committee**”).

The biographic details of Dr. Zhou are as follows:

Dr. Zhou, aged 69, had been an independent non-executive Director since 8 November 2022 and was responsible for supervising the management of our Group and providing independent judgement to the Board. Dr. Zhou was also a member of the Audit Committee and the Nomination Committee. Dr. Zhou has over 31 years of experience in hospital management and clinical research with a focus in the areas of stomatology and dentistry. During the period from 1985 to 2016, Dr. Zhou had held multiple positions at the Stomatology Hospital of Anhui Medical University\* (安徽醫科大學附屬口腔醫院). From 2000 to 2012, he served as the dean of the aforesaid hospital. Since February 2016, Dr. Zhou has served as the dean of Anhui Swan Lake Stomatological Hospital Holdings Co., Ltd.\* (安徽天鵝湖口腔醫院股份有限公司).

Dr. Zhou graduated with a bachelor's degree in stomatology from Shanghai Jiao Tong University School of Medicine\* (上海交通大學醫學院) (formerly known as Shanghai Second Medical University\* (上海第二醫學院)) in the PRC in December 1976. He further obtained a master's degree in medicine from Xi'an Medical University\* (西安醫科大學) (currently known as Xi'an Jiaotong University Health Science Centre\* (西安交通大學醫學部)) in the PRC in December 1985. In June 2014, Dr. Zhou was appointed as the honorary president of the first committee of Anhui Stomatological Association\* (安徽省口腔醫學會). Since September 2011, Dr. Zhou has served as a standing director of the Chinese Stomatological Association\* (中華口腔醫學會). He has also served as the vice president of the Asia Pacific Dental Implantology Association since September 2018. Apart from holding several public position, Dr. Zhou has received a number of recognitions for his achievement in the dental field. Dr. Zhou received the second class award from the State Education Commission of the People's Republic of China\* (中華人民共和國國家教育委員會) for his research in maxillofacial surgery, and further awarded the third class Science and Technology Progress Award for his achievement in developing techniques for applications in oral and maxillofacial surgery by the Science and Technology Progress Award Review Committee of Anhui Province\* (安徽省科學技術進步獎評審委員會) in 1998 and 2000, respectively.

At the date hereof, Dr. Zhou does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of Laws of Hong Kong). Save as disclosed above, Dr. Zhou does not hold any other positions in the Company or any members of the Group, and did not hold any directorships in any listed public companies in the past three years. He does not have any relationships with any Directors, senior management or substantial or controlling shareholders of the Company.

Dr. Zhou has entered into a service contract with the Company for a term of three years which is terminable by either party by serving to another party one month's advance written notice. His directorship is subject to retirement by rotation and re-election at the Company's annual general meeting in accordance with the articles of association of the Company. He is entitled to a director's fee of RMB144,000 per annum. His remuneration is determined by the Board with regard to his duties and responsibilities, the recommendation made by the remuneration committee of the Company (the "**Remuneration Committee**") and the prevailing market conditions.

Save as disclosed above, there is no other matter relating to Dr. Zhou's re-designation that need to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to any requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

## (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Zhang Yongcun (“**Mr. Zhang**”) has been appointed as an independent non-executive director of the Company, and will serve as a member of the Audit Committee and of the Nomination Committee, with effect from 29 November 2024.

The biographic details of Mr. Zhang are as follows:

Mr. Zhang, aged 39, has over 13 years of experience in capital markets and corporate legal advising. From July 2011 to June 2022, he served as a lawyer at Beijing Dacheng Law Offices (Zhengzhou Office)\* (北京大成(鄭州)律師事務所). Since August 2022, he has joined Blossom & Credit Law Firm\* (北京市邦盛律師事務所) as a lawyer, and subsequently become a partner and the director of Blossom & Credit Law Firm (Zhengzhou Office)\* (北京邦盛(鄭州)律師事務所).

Mr. Zhang graduated with a master’s degree in law from the Northwest University of Political Science and Law\* (西北政法大學) in the PRC in July 2011. He acquired the Lawyer’s Practicing Certificate in February 2013. He further obtained a master’s degree in executive business administration from Peking University\* (北京大學) in the PRC in July 2024. Furthermore, he was selected as an expert of Henan Province’s Share Reform Expert Service Team\* (河南省規改股專家服務團隊專家) in July 2023. He was further recognized as a member of the “Top Ten Strategies” Lawyer Expert Database of Zhengzhou Law Association\* (鄭州市律師協會服務「十大戰略」律師專家庫) in December 2023.

Mr. Zhang has entered into a letter of appointment with the Company as an independent non-executive director of the Company for an initial term of three years commencing from the date of his appointment. Mr. Zhang will hold office until the first general meeting of the Company after his appointment and will thereafter be subject to retirement by rotation and re-election in accordance with the provisions of the articles of association of the Company. Mr. Zhang is entitled to a director’s fee of RMB72,000 per annum. His remuneration is determined by the Board with regard to his duties and responsibilities, the recommendation made by the Remuneration Committee and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Zhang (i) did not hold any position with the Company or other members of the Group; (ii) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement and did not have any other major appointments and professional qualifications; (iii) did not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (iv) did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) had no other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Mr. Zhang confirmed that (a) he met all the independence criteria as set out in Rule 3.13 of the Listing Rules; (b) he had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of appointment.

The Board would like to extend its warmest welcome to Dr. Zhou and Mr. Zhang for their new appointments.

By order of the Board  
**Meihao Medical Group Co., Ltd**  
**Mr. Wang Xiaomin**  
*Chairman and executive Director*

Hong Kong, 29 November 2024

*As at the date of this announcement, the executive Directors are Mr. Wang Xiaomin, Ms. Zheng Man and Dr. Zhou Jian, and the independent non-executive Directors are Mr. Ng Ming Chee, Ms. Tam Hon Shan Celia and Mr. Zhang Yongcun.*

\* *For identification purposes only*